$1.51
3.82% yesterday
Nasdaq, Apr 03, 10:08 pm CET
ISIN
US05280R1005
Symbol
AUTL
Sector
Industry

Autolus Therapeutics plc Stock price

$1.51
-0.24 13.71% 1M
-2.39 61.28% 6M
-0.84 35.74% YTD
-3.98 72.50% 1Y
-2.87 65.53% 3Y
-3.87 71.93% 5Y
-23.49 93.96% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.06 3.82%
ISIN
US05280R1005
Symbol
AUTL
Sector
Industry

Key metrics

Market capitalization $401.85m
Enterprise Value $109.63m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 10.83
P/S ratio (TTM) P/S ratio 39.71
P/B ratio (TTM) P/B ratio 0.94
Revenue growth (TTM) Revenue growth 496.00%
Revenue (TTM) Revenue $10.12m
EBIT (operating result TTM) EBIT $-240.79m
Free Cash Flow (TTM) Free Cash Flow $-228.35m
Cash position $589.45m
EPS (TTM) EPS $-0.87
P/E forward negative
P/S forward 10.91
EV/Sales forward 2.98
Short interest 4.52%
Show more

Is Autolus Therapeutics plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Autolus Therapeutics plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Autolus Therapeutics plc forecast:

11x Buy
100%

Analyst Opinions

11 Analysts have issued a Autolus Therapeutics plc forecast:

Buy
100%

Financial data from Autolus Therapeutics plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
10 10
495% 495%
100%
- Direct Costs 19 19
191% 191%
189%
-8.98 -8.98
84% 84%
-89%
- Selling and Administrative Expenses 86 86
155% 155%
846%
- Research and Development Expense 138 138
6% 6%
1,368%
-233 -233
38% 38%
-2,303%
- Depreciation and Amortization 7.72 7.72
18% 18%
76%
EBIT (Operating Income) EBIT -241 -241
37% 37%
-2,379%
Net Profit -221 -221
6% 6%
-2,180%

In millions USD.

Don't miss a Thing! We will send you all news about Autolus Therapeutics plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Autolus Therapeutics plc Stock News

Neutral
GlobeNewsWire
2 days ago
LONDON, April 02, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in the 24th Annual Needham Virtual Healthcare Conference. Autolus Chief Executive Officer Dr. Christian Itin will present in a Fire...
Neutral
GlobeNewsWire
3 days ago
LONDON, April 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announced that the Company will host an R&D investor event on Wednesday, April 23, 2025 at 8:30am EDT / 13:30pm BST. Autolus will present an update on clinical pipeline progra...
Neutral
Seeking Alpha
15 days ago
Autolus Therapeutics plc (NASDAQ:AUTL ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Amanda Cray - IR Christian Itin - CEO Rob Dolski - CFO Conference Call Participants James Shin - Deutsche Bank Rajan Sharma - Goldman Sachs Asthika Goonewardene - Truist Matt Phipps - William Blair Gil Blum - Needham & Company Kelly Shi - Jefferies Yanan Zhu - Wells Fargo Jaco...
More Autolus Therapeutics plc News

Company Profile

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Christian Itin
Employees 647
Founded 2014
Website www.autolus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today